Biotech Stock Update: Biotech Stock Gilead Scores Legal Victory Over Roche for Sovaldi

Shares of Gilead Sciences (GILD) gained 3.25% to close the trading session on Aug 15 at $99.45 per share following the favorable verdict by an arbitration panel in a patent infringement case with Roche (RHHBY). The tussle was regarding Gilead’s blockbuster hepatitis C drug, Sovaldi (sofosbuvir). Gilead received further encouraging news on Sovaldi when U.K.’s…

Read More